Catheter Precision Inc. ($VTAK) has completed its acquisition of the remaining 80.02% equity stake in Fly Flyte Inc. from Creatd Inc. ($CRTDD), achieving 100% ownership of the regional aviation operator. The transaction, announced as a definitive merger agreement, transforms $VTAK into a diversified holding company with meaningful exposure to the aviation industry while establishing a fully consolidated operating subsidiary with FAA Part 135 certification and active revenue-generating flight operations.
The all-cash acquisition marks a significant strategic pivot for Catheter Precision, which previously held a minority stake in Fly Flyte. By acquiring the remaining 80.02% stake from Creatd Inc., $VTAK eliminates minority interest complexities and gains complete operational control of the aviation subsidiary. Fly Flyte operates as a certified regional air charter service with a fleet of aircraft that hold active FAA Part 135 certification, enabling the company to legally conduct revenue-generating charter flights for commercial purposes.
Key Details of the Acquisition
The completion of this transaction represents the culmination of $VTAK's strategic expansion into the aviation sector. Key elements of the deal include:
- 100% ownership stake achieved through acquisition of remaining 80.02% equity interest
- Fly Flyte converted into wholly-owned operating subsidiary structure
- FAA Part 135 certification maintained, permitting commercial charter operations
- Certified aircraft fleet with active revenue-generating operations
- Consolidated financial reporting enabling full P&L consolidation going forward
The acquisition structure positions Fly Flyte as a certified operating subsidiary rather than a passive investment, meaning its financial performance will now flow directly into $VTAK's consolidated results. This eliminates accounting complications associated with equity method accounting that $VTAK previously used for its minority stake. The FAA Part 135 certification is particularly significant, as obtaining such certification typically requires substantial time, capital investment, and regulatory scrutiny—assets that Fly Flyte already possesses.
Market Context and Strategic Implications
Catheter Precision's transformation from a medical device-focused company to an asset-backed aviation platform represents an unconventional diversification strategy in the public markets. The regional aviation charter sector has experienced modest growth in recent years, driven by corporate demand for flexible transportation alternatives and the gradual recovery of business travel post-pandemic.
The regional charter aviation market remains highly fragmented, with numerous small operators competing alongside larger players like NetJets (a Berkshire Hathaway subsidiary). However, the FAA Part 135 certification provides a significant competitive moat, as regulatory barriers to entry protect established operators from casual competitors. The certified aircraft fleet represents tangible assets on the balance sheet, providing collateral value and operational infrastructure.
This acquisition reflects broader trends of strategic acquisitions seeking to leverage existing regulatory certifications and operational assets. By consolidating Fly Flyte as a wholly-owned subsidiary, $VTAK gains immediate revenue streams without the extended timelines required to build aviation operations from scratch. The move also addresses the distinction between minority equity stakes and consolidatable operating subsidiaries—a critical factor for financial reporting and investor valuation.
Investor Implications and Financial Impact
The completion of the Fly Flyte acquisition carries several material implications for Catheter Precision shareholders:
Balance Sheet and Reporting: Going forward, Fly Flyte's revenues, operating expenses, and assets will consolidate fully into $VTAK's financial statements. This should significantly increase reported revenues and provide greater transparency into the aviation subsidiary's operational performance. Previously, $VTAK's minority stake was reported under equity method accounting, limiting visibility into detailed operational metrics.
Asset Backing and Tangible Value: The certified aircraft fleet and FAA certifications provide tangible assets backing the subsidiary's value. These assets create operational optionality and collateral that could support future financing or strategic transactions.
Operating Leverage Potential: As a wholly-owned subsidiary with established revenue operations, Fly Flyte positions $VTAK to capture operational improvements and cost synergies. The consolidated structure enables centralized management decisions regarding pricing, route optimization, and fleet utilization.
Sector Diversification: The acquisition fundamentally reshapes $VTAK's investor profile from a pure-play medical device company to a diversified holding company with aviation sector exposure. This diversification may appeal to or alienate different investor segments, potentially affecting $VTAK's valuation multiples and peer comparisons.
Cash Requirements: The transaction required cash outlay to acquire the 80.02% stake from Creatd Inc., which impacts $VTAK's liquidity position and may influence future capital allocation priorities. Investors should monitor cash flow statements to assess whether aviation operations generate sufficient returns to justify the acquisition capital.
The regional aviation sector's cyclicality warrants attention—charter demand correlates closely with corporate profitability and business sentiment, making Fly Flyte's revenue streams sensitive to economic downturns. However, the FAA Part 135 certification and established operations provide a revenue floor unavailable to startups in the sector.
Looking Forward
Catheter Precision's completion of the Fly Flyte acquisition represents a fundamental strategic repositioning for the company. The transformation from minority equity holder to majority operating company owner should provide consolidated financial visibility and operational leverage potential. Success will depend on $VTAK's ability to optimize Fly Flyte's operations, maintain its regulatory certifications, and generate returns on the acquisition capital invested.
Investors should monitor upcoming quarterly results to assess Fly Flyte's consolidated contribution to revenues and operating margins. The fully consolidated subsidiary structure enables direct evaluation of aviation sector profitability, a metric previously obscured by equity method accounting. The acquisition establishes $VTAK as an asset-backed platform with immediate operational cash flows—a materially different risk-return profile than its previous business model.